Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR088 in Relapsed or Refractory Multiple Myeloma
NCT04295018Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2019
- Primary completion
- Sep 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trovocabtagene autoleucel in multiple myeloma (MM), sponsored by Peking Union Medical College Hospital. Primary endpoint: Incidence of adverse events at 30 days. Status: unknown.
02
Drugs
trovocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04295018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295018.